Global pharmaceutical company Merck (NYSE: MRK) beat Wall Street’s revenue expectations in Q2 CY2026, with sales up 5.1% year on year to $16.61 billion. The company expects the full year’s revenue to be around $66.8 billion, close to analysts’ estimates. Its non-GAAP loss of $0.13 per share was 49.5% above analysts’ consensus estimates.
Is now the time to buy MRK? Find out in our full research report (it’s free for active Edge members).
Merck (MRK) Q2 CY2026 Highlights:
- Revenue: $16.61 billion vs analyst estimates of $16.27 billion (5.1% year-on-year growth, 2.1% beat)
- Adjusted EPS: -$0.13 vs analyst estimates of -$0.26 (49.5% beat)
- The company slightly lifted its revenue guidance for the full year to $66.8 billion at the midpoint from $66.4 billion
- Management lowered its full-year Adjusted EPS guidance to $2.71 at the midpoint, a 46.9% decrease
- Operating Margin: -3.5%, down from 31.6% in the same quarter last year
- Constant Currency Revenue rose 4% year on year (-2% in the same quarter last year)
- Market Capitalization: $316.1 billion
StockStory’s Take
Merck's second quarter was marked by continued sales growth, primarily driven by the strength of its oncology portfolio and contributions from new product launches. Management credited higher demand for KEYTRUDA in both early-stage and metastatic cancers and robust performance in Animal Health as core drivers. CFO Caroline Litchfield highlighted, “Our strong commercial and operational execution continues to drive near-term performance while we invest in our outstanding pipeline.” While market reaction was muted, management acknowledged the impact of higher operating expenses, including acquisition-related charges, on overall profitability.
Looking ahead, Merck’s updated guidance is shaped by an expanding pipeline and expectations for increasing contributions from newly approved therapies, particularly in cardiometabolic and HIV segments. CEO Robert Davis stated, “We remain confident in our outlook... supported by global demand for our innovative medicines and vaccines, including our many new product launches.” However, management cautioned that margin pressures and ongoing investment in pipeline development may moderate earnings growth through the rest of the year.
Key Insights from Management’s Remarks
Management attributed Q2 performance to sustained oncology growth, successful new product launches, and significant pipeline advances, while noting that increased investment and acquisition costs weighed on margins.
- Oncology strength: Sales of KEYTRUDA and KEYTRUDA QLEX rose due to increased use in early-stage and metastatic cancers, and new combinations, particularly in indications like breast, cervical, and urothelial cancers.
- New product launches: The launch of LIPFENDRA, the first oral PCSK9 inhibitor for cholesterol reduction, and IDVYNSO, a new HIV therapy, contributed early to growth, though management expects adoption to be gradual as payer access is established.
- Pipeline advancement: Merck highlighted regulatory milestones, including positive Phase III data for several assets such as sac-TMT (an antibody-drug conjugate in endometrial cancer), tulisokibart (for ulcerative colitis), and new studies in HIV and influenza prevention.
- Animal Health momentum: Growth in both livestock and companion animal segments was attributed to new product launches and higher demand, supporting broader revenue diversification.
- Margin compression drivers: Operating expenses grew significantly due to the Terns Pharmaceuticals acquisition and ongoing investments in clinical programs, resulting in a non-GAAP loss for the quarter despite top-line growth.
Drivers of Future Performance
Merck’s full-year outlook depends on sustained demand for its new launches, the pace of clinical trial progress, and the ability to offset margin headwinds from increased investment.
- Pipeline execution risk: Management emphasized the importance of timely clinical readouts and regulatory approvals for late-stage assets in oncology, immunology, and infectious diseases as major contributors to future revenue.
- Adoption of new therapies: The company expects a gradual ramp in LIPFENDRA and IDVYNSO adoption, with broader uptake tied to payer access, physician education, and updated treatment guidelines, especially in primary care channels for cholesterol management.
- Margin pressures and investment: Ongoing R&D spending and integration of Terns Pharmaceuticals are expected to weigh on operating margins and profit growth in the near term, with management aiming for long-term value creation through portfolio diversification.
Catalysts in Upcoming Quarters
In future quarters, StockStory analysts will monitor (1) continued adoption and access for LIPFENDRA and IDVYNSO, (2) pivotal clinical trial readouts for sac-TMT, tulisokibart, and key HIV assets, and (3) the pace of margin recovery as integration costs and R&D investments are absorbed. Ongoing product launches and regulatory milestones will be important markers of execution.
Merck currently trades at $128.36, in line with $127.77 just before the earnings. Is the company at an inflection point that warrants a buy or sell? See for yourself in our full research report (it’s free).
Stocks That Trumped Tariffs
ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.
Find out which 5 stocks it’s flagging this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+1,154% between June 2020 and June 2025). Find your next big winner with StockStory today.
